Does neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer obliterate survival differences between genders?

ABSTRACT:

Background

The 5-year survival rate in muscle-invasive bladder cancer (MIBC) is approximately 50%, cross over computed tomography (CT) stage in chemo-naive patients. Studies indicate lower survival rates in females when compared to males. The theories that explain the sex disparity are hormonal factors and delayed diagnosis for females. New investigations suggest that neoadjuvant chemotherapy (NAC) might be a possible method for bridging the gender survival gap. The aim of this study was to investigate whether complete treatment with NAC (≥3 cycles) prior to cystectomy reduces the gender gap in survival rates for MIBC and improves the surrogate marker of downstaging.

Methods

A multicenter retrospective cohort from five Swedish urological centers, from 1st January 2005 to 17t

SUBMITTER: Sidiqi G 

PROVIDER: S-EPMC12271936 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature